Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified Phl p 1
- Development stage
- Preclinical
- Lead developer
- Desentum
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Modified Phl p 1 is a recombinant hypoallergen developed by Desentum for the treatment of grass pollen allergy. It is a genetically engineered version of Phl p 1, the major allergen in Timothy grass (*Phleum pratense*) pollen. The protein has been modified to significantly reduce its IgE-binding capacity, which minimizes the risk of allergic reactions during administration, while preserving the T-cell epitopes necessary to induce long-term immunological tolerance. Intended for subcutaneous immunotherapy (SCIT), the drug aims to provide a safer and more efficient alternative to traditional allergen extracts used in desensitization therapy by promoting the production of protective IgG antibodies and modulating T-cell responses.
- Other names
- grass pollen hypoallergen (Modified Phl p 1)recombinant Phl p 1 hypoallergenModified Phl p 1
02
Targets
TCR (T cell antigen receptor complex)EXPB1 (Group 1 beta-expansin)Phl p 1-specific immunoglobulin E
Beyond the preview
Go deeper on modified Phl p 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified Phl p 1.